Market closed
Aligos Therapeutics/$ALGS
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About Aligos Therapeutics
Aligos Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapeutics to address unmet medical needs in viral and liver diseases, including chronic hepatitis B and coronaviruses, and therapeutics for nonalcoholic steatohepatitis (NASH). The company's pipeline includes ALG-010133, ALG-000184, ALG-020572 and ALG-055009, among others.
Ticker
$ALGS
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
68
Website
ALGS Metrics
BasicAdvanced
$37M
Market cap
-
P/E ratio
-
EPS
-
Beta
-
Dividend rate
Price and volume
Market cap
$37M
52-week high
$30.00
52-week low
$6.76
Average daily volume
105K
Financial strength
Current ratio
3.809
Quick ratio
3.575
Long term debt to equity
11.444
Total debt to equity
18.231
Management effectiveness
Return on assets (TTM)
-67.32%
Return on equity (TTM)
-146.69%
Valuation
Growth
Revenue change (TTM)
-63.40%
3-year revenue growth (CAGR)
14.53%
ALGS News
AllArticlesVideos
Aligos Therapeutics Reports Recent Business Progress and Third Quarter 2024 Financial Results
GlobeNewsWire·2 days ago
Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewsWire·4 weeks ago
Aligos Therapeutics Appoints David Perry as Vice President of Business Development
GlobeNewsWire·1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Aligos Therapeutics stock?
Aligos Therapeutics (ALGS) has a market cap of $37M as of November 08, 2024.
What is the P/E ratio for Aligos Therapeutics stock?
The price to earnings (P/E) ratio for Aligos Therapeutics (ALGS) stock is 0 as of November 08, 2024.
Does Aligos Therapeutics stock pay dividends?
No, Aligos Therapeutics (ALGS) stock does not pay dividends to its shareholders as of November 08, 2024.
When is the next Aligos Therapeutics dividend payment date?
Aligos Therapeutics (ALGS) stock does not pay dividends to its shareholders.
What is the beta indicator for Aligos Therapeutics?
Aligos Therapeutics (ALGS) does not currently have a Beta indicator.